Hims & Hers Health Inc. (HIMS) experienced a significant 24-hour plunge of 7.35%, with the sharp decline occurring in after-hours trading on Monday.

The drop is primarily attributed to the company's mixed fourth-quarter 2025 financial results. While earnings per share beat analyst estimates, revenue of $617.8 million slightly missed expectations. More critically, the company issued first-quarter 2026 revenue guidance of $600 million to $625 million, which fell substantially short of Wall Street forecasts, casting doubt on near-term growth prospects.

Adding to investor concerns, a regulatory filing highlighted uncertainty regarding potential actions by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS), or Department of Justice (DOJ) concerning the marketing of compounded GLP-1 products, a treatment area the company is involved in. This regulatory overhang, combined with a noted decline in gross margin, contributed to the after-hours sell-off.